A pharmaceutical company representative described the Access to Medicine Index 2016 as “a force for good, and not yet another stick with which to beat industry”.1 The Access to Medicine Index 2016,1 which will be presented at a public meeting later this month at the time of the WHO Executive Board meeting in Geneva, ranks the top 20 research-based pharmaceutical companies on their efforts to improve access to medicine in low-income and middle-income countries (LMICs). And those companies with high ranking tout their success to their stockholders and the media.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iPVL7x
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction che...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jCvX3K via IFTTT
-
Dental implants are now broadly used to replace missing teeth, and the presence of infectious complications is rising. Dental implant therap...
-
Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement. ...
-
Abstract Purpose Accurate and real-time prediction of the lung and lung tumor deformation during respiration are important consideration...
-
Abstract Purpose of Review Our goal is to summarize the airway disease literature since September 11, 2001 (9/11), focusing on studies pub...
-
Treatment effectiveness holds considerable importance in the association between service quality and satisfaction in medical service studies...
-
Therapeutic agents designed to stimulate the immune system are now cornerstones in the treatment of metastatic melanoma. These drugs promote...
-
Coenzyme Q (CoQ) is a key component of the mitochondrial respiratory chain, but it also has several other functions in the cellular metaboli...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου